和记黄埔医药宣布向GSK授权KRAS-EGFR抗体偶联疗法海外权益
6-K - HUTCHMED (China) Ltd (0001648257) (Filer)
和记黄埔医药宣布向GSK授权KRAS-EGFR抗体偶联疗法海外权益。该授权涵盖除中国外的全球市场。此次交易未披露具体金额。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2026
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. | | Description |
| | |
Exhibit 99.1 | | Press release relating to HUTCHMED announces closing of KRAS-EGFR-antibody conjugate therapy license to GSK outside China |
| | |
| | |
| | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUTCHMED (CHINA) LIMITED | |
| | |
| | |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |
Date: October 21, 2026
3
来源：SEC EDGAR · 本站存档